Effects of cranberry beverage on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial

2021 ◽  
Author(s):  
Tao Gao ◽  
Meiling Hou ◽  
Bo Zhang ◽  
Xin Pan ◽  
Chengxia Liu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Controlled Trial ◽  
Gastric Diseases ◽  
Oxidative Stress Biomarkers ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Stress Biomarkers ◽  
H Pylori

Helicobacter pylori-induced oxidative stress plays an important role in gastric diseases. H. pylori disturbs gut microbiota. The objective is to investigate the effects of cranberry beverages on oxidative stress biomarkers...

scholarly journals Antioxidative Efficacy of a Pistacia Lentiscus Supplement and Its Effect on the Plasma Amino Acid Profile in Inflammatory Bowel Disease: A Randomised, Double-Blind, Placebo-Controlled Trial

Nutrients ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1779 ◽  
Author(s):  
Efstathia Papada ◽  
Alastair Forbes ◽  
Charalampia Amerikanou ◽  
Ljilja Torović ◽  
Nick Kalogeropoulos ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Inflammatory Bowel Disease ◽  
Amino Acid ◽  
Density Lipoprotein ◽  
Pistacia Lentiscus ◽  
Oxidative Stress Biomarkers ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Stress Biomarkers ◽  
Inflammatory Bowel

Oxidative stress is present in patients with Inflammatory Bowel Disease (IBD), and natural supplements with antioxidant properties have been investigated as a non-pharmacological approach. The objective of the present study was to assess the effects of a natural Pistacia lentiscus (PL) supplement on oxidative stress biomarkers and to characterise the plasma-free amino acid (AA) profiles of patients with active IBD (Crohn’s disease (CD) N = 40, ulcerative colitis (UC) N = 20). The activity was determined according to 5 ≤ Harvey Bradshaw Index ≤ 16 or 2 ≤ Partial Mayo Score ≤ 6. This is a randomised, double-blind, placebo-controlled clinical trial. IBD patients (N = 60) were randomly allocated to PL (2.8 g/day) or to placebo for 3 months being under no treatment (N = 21) or under stable medical treatment (mesalamine N = 24, azathioprine N = 14, and corticosteroids N = 23) that was either single medication (N = 22) or combined medication (N = 17). Plasma oxidised, low-density lipoprotein (oxLDL), total serum oxidisability, and serum uric acid were evaluated at baseline and follow-up. OxLDL/LDL and oxLDL/High-Density Lipoprotein (HDL) ratios were calculated. The plasma-free AA profile was determined by applying a gas chromatography/mass spectrometry analysis. oxLDL (p = 0.031), oxLDL/HDL (p = 0.020), and oxLDL/LDL (p = 0.005) decreased significantly in the intervention group. The mean change differed significantly in CD between groups for oxLDL/LDL (p = 0.01), and, in the total sample, both oxLDL/LDL (p = 0.015) and oxLDL/HDL (p = 0.044) differed significantly. Several changes were reported in AA levels. PL ameliorated a decrease in plasma-free AAs seen in patients with UC taking placebo. In conclusion, this intervention resulted in favourable changes in oxidative stress biomarkers in active IBD.

Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial

2018 ◽  
Vol 9 (12) ◽  
pp. 6508-6516 ◽  
Author(s):  
Marta Esgalhado ◽  
Julie A. Kemp ◽  
Renata Azevedo ◽  
Bruna R. Paiva ◽  
Milena B. Stockler-Pinto ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Resistant Starch ◽  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Uremic Toxins ◽  
Oxidative Stress Biomarkers ◽  
Randomized Controlled ◽  
Stress Biomarkers ◽  
And Oxidative Stress ◽  
Pilot Randomized Controlled Trial

Prebiotic-resistant starch supplementation may be a good strategy to reduce inflammation, oxidative stress and uremic toxins in CKD patients.

scholarly journals A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy

Nutrients ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 3171
Author(s):  
Eric Guillemard ◽  
Marion Poirel ◽  
Florent Schäfer ◽  
Laurent Quinquis ◽  
Caroline Rossoni ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Beta Diversity ◽  
Pathogenic Bacteria ◽  
Controlled Trial ◽  
Eradication Therapy ◽  
Fermented Milk ◽  
Control Group ◽  
Double Blind ◽  
Gi Symptoms

Helicobacter pylori (Hp) eradication therapy alters gut microbiota, provoking gastrointestinal (GI) symptoms that could be improved by probiotics. The study aim was to assess the effect in Hp patients of a Test fermented milk containing yogurt and Lacticaseibacillus (L. paracasei CNCM I-1518 and I-3689, L. rhamnosus CNCM I-3690) strains on antibiotic associated diarrhea (AAD) (primary aim), GI-symptoms, gut microbiota, and metabolites. A randomised, double-blind, controlled trial was performed on 136 adults under 14-day Hp treatment, receiving the Test or Control product for 28 days. AAD and GI-symptoms were reported and feces analysed for relative and quantitative gut microbiome composition, short chain fatty acids (SCFA), and calprotectin concentrations, and viability of ingested strains. No effect of Test product was observed on AAD or GI-symptoms. Hp treatment induced a significant alteration in bacterial and fungal composition, a decrease of bacterial count and alpha-diversity, an increase of Candida and calprotectin, and a decrease of SCFA concentrations. Following Hp treatment, in the Test as compared to Control group, intra-subject beta-diversity distance from baseline was lower (padj = 0.02), some Enterobacteriaceae, including Escherichia-Shigella (padj = 0.0082) and Klebsiella (padj = 0.013), were less abundant, and concentrations of major SCFA (p = 0.035) and valerate (p = 0.045) were higher. Viable Lacticaseibacillus strains were detected during product consumption in feces. Results suggest that, in patients under Hp treatment, the consumption of a multi-strain fermented milk can induce a modest but significant faster recovery of the microbiota composition (beta-diversity) and of SCFA production and limit the increase of potentially pathogenic bacteria.

Sign in / Sign up

Export Citation Format

Share Document